S&P 500   3,121.21 (-0.03%)
DOW   27,934.98 (-0.36%)
QQQ   203.40 (+0.16%)
CGC   15.22 (+7.03%)
BABA   184.55 (-0.04%)
GE   11.51 (+0.61%)
T   38.07 (-3.94%)
ACB   2.35 (+3.08%)
F   8.91 (-0.45%)
BAC   32.96 (-0.03%)
DIS   148.29 (+0.43%)
S&P 500   3,121.21 (-0.03%)
DOW   27,934.98 (-0.36%)
QQQ   203.40 (+0.16%)
CGC   15.22 (+7.03%)
BABA   184.55 (-0.04%)
GE   11.51 (+0.61%)
T   38.07 (-3.94%)
ACB   2.35 (+3.08%)
F   8.91 (-0.45%)
BAC   32.96 (-0.03%)
DIS   148.29 (+0.43%)
S&P 500   3,121.21 (-0.03%)
DOW   27,934.98 (-0.36%)
QQQ   203.40 (+0.16%)
CGC   15.22 (+7.03%)
BABA   184.55 (-0.04%)
GE   11.51 (+0.61%)
T   38.07 (-3.94%)
ACB   2.35 (+3.08%)
F   8.91 (-0.45%)
BAC   32.96 (-0.03%)
DIS   148.29 (+0.43%)
S&P 500   3,121.21 (-0.03%)
DOW   27,934.98 (-0.36%)
QQQ   203.40 (+0.16%)
CGC   15.22 (+7.03%)
BABA   184.55 (-0.04%)
GE   11.51 (+0.61%)
T   38.07 (-3.94%)
ACB   2.35 (+3.08%)
F   8.91 (-0.45%)
BAC   32.96 (-0.03%)
DIS   148.29 (+0.43%)
Log in

Neuralstem Stock Price, Forecast & Analysis (NASDAQ:CUR)

$1.52
-0.31 (-16.94 %)
(As of 10/31/2019)
Today's Range
$1.48
Now: $1.52
$1.81
50-Day Range
$1.15
MA: $1.42
$1.88
52-Week Range
$1.10
Now: $1.52
$13.78
Volume2.10 million shs
Average Volume1.98 million shs
Market Capitalization$3.19 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Neuralstem, Inc, a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CUR
CUSIPN/A
Phone301-366-4841

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$260,000.00
Book Value$6.64 per share

Profitability

Net Income$-4,930,000.00
Net Margins-39,417.64%

Miscellaneous

Employees6
Market Cap$3.19 million
Next Earnings DateN/A
OptionableOptionable

Receive CUR News and Ratings via Email

Sign-up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.


Neuralstem (NASDAQ:CUR) Frequently Asked Questions

What is Neuralstem's stock symbol?

Neuralstem trades on the NASDAQ under the ticker symbol "CUR."

When did Neuralstem's stock split? How did Neuralstem's stock split work?

Neuralstem's stock reverse split on Thursday, July 18th 2019. The 1-20 reverse split was announced on Tuesday, July 16th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 17th 2019. An investor that had 100 shares of Neuralstem stock prior to the reverse split would have 5 shares after the split.

How were Neuralstem's earnings last quarter?

Neuralstem, Inc. (NASDAQ:CUR) released its earnings results on Wednesday, August, 14th. The company reported ($1.45) EPS for the quarter. The firm earned $0.01 million during the quarter. Neuralstem had a negative net margin of 39,417.64% and a negative return on equity of 170.51%. View Neuralstem's Earnings History.

Has Neuralstem been receiving favorable news coverage?

Headlines about CUR stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neuralstem earned a daily sentiment score of 1.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Neuralstem.

Who are some of Neuralstem's key competitors?

What other stocks do shareholders of Neuralstem own?

Who are Neuralstem's key executives?

Neuralstem's management team includes the folowing people:
  • Dr. Kenneth C. Carter, Exec. Chairman, CEO & Principal Financial Officer (Age 59)
  • Dr. Karl Y. Johe, Co-Founder (Age 59)
  • Dr. Thomas G. Hazel Ph.D., Sr. VP of Research
  • Dr. David P. Recker, Chief Medical Officer (Age 61)

How do I buy shares of Neuralstem?

Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neuralstem's stock price today?

One share of CUR stock can currently be purchased for approximately $1.52.

How big of a company is Neuralstem?

Neuralstem has a market capitalization of $3.19 million and generates $260,000.00 in revenue each year. Neuralstem employs 6 workers across the globe.View Additional Information About Neuralstem.

What is Neuralstem's official website?

The official website for Neuralstem is http://www.neuralstem.com/.

How can I contact Neuralstem?

Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected]


MarketBeat Community Rating for Neuralstem (NASDAQ CUR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  512
MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe CUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel